BiotechTubeBiotechTube
Home/Pipeline/Elafibranor (GFT505)

Elafibranor (GFT505)

Primary Biliary Cholangitis (PBC)

Phase 3Active - ELATIVE® trial met endpointsNCT04526665

Key Facts

Indication
Primary Biliary Cholangitis (PBC)
Phase
Phase 3
Status
Active - ELATIVE® trial met endpoints
Company
Genfit, Genfit

About Genfit

GENFIT is a French biopharmaceutical company with a 20+ year history, pioneering research in nuclear receptors and metabolic diseases. Its strategic focus is on advancing elafibranor, a first-in-class PPAR agonist, through late-stage development for PBC and exploring its potential in other liver and metabolic conditions. The company is also commercializing NIS4®, a non-invasive blood-based diagnostic technology for NASH, and maintains a discovery pipeline fueled by its integrated research platform. GENFIT is publicly traded on the Euronext Paris and Nasdaq exchanges.

View full company profile

About Genfit

GENFIT is a French biopharmaceutical company with a 20+ year history, pioneering research in nuclear receptors and metabolic diseases. Its strategic focus is on advancing elafibranor, a first-in-class PPAR agonist, through late-stage development for PBC and exploring its potential in other liver and metabolic conditions. The company is also commercializing NIS4®, a non-invasive blood-based diagnostic technology for NASH, and maintains a discovery pipeline fueled by its integrated research platform. GENFIT is publicly traded on the Euronext Paris and Nasdaq exchanges.

View full company profile

Therapeutic Areas

Metabolic DiseasesLiver DiseasesGastroenterology